Transforming the treatment of Asia prevalent cancer Dr Carl Firth CEO & Chairman Corporate presentation December 2017
Disclaimer All materials and information set out herein are for reference only and whilst we make every effort to ensure accuracy and completeness, we cannot guarantee this. We make no recommendation as to the competence or suitability of persons or entities referenced herein (if any). Nothing herein constitutes an invitation or offer to invest in or deal in the securities of ASLAN. Anyone considering investment in ASLAN should refer to the information officially published the Taiwan Stock Exchange Market Observation System (MOPS). All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on such forward-looking statements, which are inherently unreliable, and you should not rely on them. Any such forward-looking statement will have been based on ASLAN’s expectations, assumptions, estimates and projections about future events on the date(s) made. Actual outcomes are subject to numerous risks and uncertainties, many of which relate to factors beyond ASLAN’s control, that could cause them to differ materially from those expressed in a forward-looking statement. ASLAN has no obligation to update or otherwise revise any forward-looking statements to reflect the occurrence of unanticipated events or for any other reason. 2
Oncology therapeutics focused on Asia prevalent tumours • Focus on Asia prevalent tumours that are orphan diseases in West Strategy • Asia-based clinical development with Singapore HQ • In-licensing of development compounds by veteran industry team • Development pipeline of 5 drugs, IO and other targeted therapies Pipeline • Varlitinib in pivotal trials for biliary tract cancer and gastric cancer with interim data expected in 2018 and potential to file in 2019 • ASLAN003 phase 1 completed, phase 2 in AML initiated with initial data expected in early 2018 • Partnerships with world-leading pharma and biotechs including Partnering Array, BMS, CSL and Almirall • Ongoing in-licensing and out-licensing discussions • Listed on Taipei Exchange in June 2017 Financial • US$ 130M raised since inception, US$ 33M IPO proceeds • Pro forma cash balance of US$ 60M, runway into 2019 3
Company overview 4
Many Asia prevalent tumours are orphan in West Focus on tumour types that are prevalent in Asia and orphan diseases in the West Asian data can support Western approval Patients in US Patients in Asia 12,000 Biliary tract cancer (BTC) 220,000 26,000 Gastric cancer 1,200,000 27,000 Hepatocellular carcinoma 482,000 21,000 Esophageal cancer 340,000 47,000 Cervical cancer 807,000 • Studies run in Asia where the majority of patients live • Data is leveraged for approvals in US, EU and other global markets where often these are orphan diseases • Few – if any – approved therapies for these indications 5
Headquartered in Singapore, developing globally • ASLAN will commercialise in US and selected Asian markets • Will work with partners in Japan and Europe EU South Korea US Japan ASLAN China ASLAN Taiwan HK Philippines ASLAN Singapore Australia New Zealand ASLAN offices Other countries where we operate 6
Veteran management team, blockbuster experience Position Experience Dr Carl Firth Head of New Portfolio (China) Head of Asia Healthcare Banking CEO Head of BD (Asia) Dr Bertil Lindmark Head of Development, R&I Global Head of R&D CMO Head of Development, Japan CSO Dr Mark McHale Head of Molecular Sciences, R&I COO Head of Early Asthma Portfolio Jeff Tomlinson CBO Ben Goodger General Counsel Senior Partner and Head of IP Partner Kiran Asarpota VP of Finance Group Finance Director Chih-Yi Hsieh GM Taiwan, VP Medical Medical Advisor Oncologist, Taipei VGH 7
Scientific advisory board, world-renowned expertise Position Experience Sir David Lane Chairman Chief Scientist Founder and CEO Head of P53 Research Institute Professor Patrick Tan Professor Associate Director Dr Yong Wei Peng Senior Consultant Adjunct Senior Research Fellow Dr Matthew Ng Medical Oncologist Deputy Director 8
Our portfolio 9
Development pipeline Therapies target biomarker-defined subsets of disease Program Discovery Preclinical Phase 1 Phase 2 Pivotal Originator Biliary tract cancer Gastric cancer Varlitinib (ASLAN001) Breast cancer Colorectal cancer ASLAN003 AML Inflammation ASLAN004 Oncology ASLAN005 Oncology Modybodies Oncology BMS acquired global ASLAN002 Solid tumours rights in 2016 10
Varlitinib 11
Overview of Varlitinib (ASLAN001) • Small molecule based reversible pan-HER inhibitor with balanced inhibition B across all HER receptors D • Global rights (all indications) licensed from Array BioPharma U P • Studied in over 400 patients to date, with good tolerability and demonstrated efficacy in BTC, gastric, breast, CRC DA • Orphan status approved for CCA and GC by US FDA TE • Strong IP protection including composition of matter in major territories 12
Potential to block growth in range of tumours • The HER family of receptors is responsible for driving growth HERCEPTIN in many tumours HER2 • Many approved drugs target these receptors • HER-selective drugs such as Herceptin target only one type of HER receptor (HER2) Downstream signalling blocked. No growth / proliferation • Effective in certain patient subsets that are driven specifically by HER2 HERCEPTIN HER2 HER1 HER3 HER4 • Blocking just one of these receptors is ineffective for the majority of patients • Many of these are driven by combinations of HER1, HER2, Downstream signalling leading HER3 and HER4 to growth and proliferation VARLITINIB • Varlitinib is a pan-HER inhibitor that blocks all of these receptors, shutting down growth in a much broader range of tumours Downstream signalling blocked. No growth / proliferation 13
Combining with GC standard of care chemo showed impressive responses in difficult to treat tumours Phase 1b combining varlitinib with doublet chemotherapy: 60% Maximum tumour shrinkage (%) 40% 20% Response duration (wk) 32 13 48 36 32 63 30 * * * 0% -20% Tumour type n Response rate Disease control Biliary tract 15 20% 87% -40% Gastric 5 40% 100% Colorectal 11 18% 100% -60% Breast 2 0% 100% -80% Other 7 0% 86% Total 40 18% 93% -100% ASCO (2017) Abstract e15671 • All patients received 300-500mg varlitinib and doublet chemo for 6 cycles then monotherapy • Most patients had received at least 2 prior treatments, including Herceptin, Kadcyla and chemotherapy. Some patients had as many as 13 prior treatments • Not all patients have completed 4 cycles of therapy 14 * These patients did not have measurable lesions, but declared SD by investigator based on non-measurable tumour mass
Varlitinib demonstrated greater tumour shrinkage in 2nd line HER2+ mBC compared to lapatinib Randomised, open label, phase 2 varlitinib + capecitabine 2 nd line BC 50 patients enrolled patients Primary endpoint: ORR (HER2+) lapatinib + capecitabine Secondary endpoint: PFS Varlitinib Lapatinib 12-wk tumour shrinkage* 36% 18% p-value 0.075 ORR 60% 46% PFS / OS No difference (not powered for PFS/OS) • Safety: – Diarrhoea 12% grade 3, 0% grade 4 – No anti-diarrhoea prophylaxis used, all diarrhoea clinically managed • Studies ongoing in neoadjuvant BC and BC with brain metastasis * Excluding patients on therapy for less than one month 15
Biliary tract cancer Classification • BTC is a subset of liver cancer, categorised into 4 types: – IHCCA, EHCCA, gall bladder, papilla vater • Over 70% of BTC cancers express one or more HER family receptors Current treatment • 35% patients undergo surgical resection, however BTC patients recurrence rate over 65% • No therapies globally approved. Chemotherapy typically 1 st line used off-label • Poor prognosis with two year survival less than 10% and Chemo (gem/cis) PFS 8 mon median overall survival 11 months 2 nd line Drugs in development • FGFR2 and IDH1 inhibitors, both in phase 3, target a Chemo (cap) PFS 3 mon 10% subset of patients Varlitinib target patients 16
Biliary tract cancer Global market size US$1,400M US EU5 China Japan 170,000 BTC patients 12,000 BTC patients 13,000 BTC patients 20,000 BTC patients 18,000 target 10,000 target 6,000 target 7,000 target Market $240M Market $270M Market $350M Market $220M Target patients: • Unresectable • Eligible for chemotherapy • 2 nd line • In China: can afford innovative drug 17
Biliary tract cancer – the pivotal TreeTopp study • Pivotal “TreeTopp” study initiated in April 2017 in 2nd line BTC – 60 sites including US, EU, Japan, China, AsiaPac – Led by Dr Milind Javle (MD Anderson) – Study design agreed with US FDA – Retrospective analysis of HER biomarkers • Potential to file for approval in 2019 • Also running: – 1st line BTC study – Pivotal China BTC study Double-blind, randomised varlitinib + capecitabine Placebo-controlled 2 nd line BTC 120 patients patients Primary endpoint: ORR capecitabine Secondary endpoints: PFS, OS 18
Recommend
More recommend
